SELLAS LIFE SCIENCES GROUP INC (SLS)
Health Care · Clinical-stage oncology immunotherapy · NASDAQ
Clinical-stage cancer immunotherapy company developing WT1-targeted peptide immunotherapy and CDK9 inhibitors with a Phase 3 AML trial underway.
What SELLAS LIFE SCIENCES GROUP INC does
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapeutics. Its lead product, galinpepimut-S (GPS), is a peptide immunotherapy targeting the WT1 antigen for hematologic and solid tumor indications, currently in a Phase 3 trial for acute myeloid leukemia. The company also develops SLS009, a selective CDK9 inhibitor small molecule for cancer, and operates with rights primarily outside Greater China through licensing agreements.
Themes: ["cancer immunotherapy / immunotherapy","acute myeloid leukemia (AML)","solid tumor oncology","CDK inhibitors / cell cycle control"]
Fundamentals
- Price$13.51 as of 2026-07-09 close
- Market cap$2.6B as of 2026-07-10
- 1-year return+611.1% as of 2026-07-09 close
- Net margin-736.2% as of 2026-07-10
- Gross margin+93.1% as of 2026-07-10
- ROE-47.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta2.48 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: GPS in Phase 3 REGAL trial for AML is event-driven and timing of final analysis is unpredictable; trial outcome may not meet statistically significant or clinically meaningful threshold needed for BLA submission.","Licensing and regulatory risk: Company has entered binding arbitration with 3D Medicines over disputed milestone payments; dependence on licensing agreements and third-party commercialization partners for Greater China territory.","Capital and funding risk: Company is unprofitable with highly negative net margin (-736%); continued development requires significant capital raises and ability to fund clinical trials without near-term revenue generation."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.